{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:32:14Z","timestamp":1767897134230,"version":"3.49.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00210-020-01901-6","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T08:06:46Z","timestamp":1589875606000},"page":"1137-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19)"],"prefix":"10.1007","volume":"393","author":[{"given":"Maryam","family":"Rameshrad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Ghafoori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Hooshang","family":"Mohammadpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Javad Dehghan","family":"Nayeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-851X","authenticated-orcid":false,"given":"Hossein","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"1901_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","volume":"24","author":"M Adnan Shereen","year":"2020","unstructured":"Adnan Shereen M, Khan S, Kazmi A, Bashir N, Siddique R (2020) COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 24:91\u201398. https:\/\/doi.org\/10.1016\/j.jare.2020.03.005","journal-title":"J Adv Res"},{"key":"1901_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1128\/jvi.79.3.1966-1969.2005","volume":"79","author":"S \u00c5kerstr\u00f6m","year":"2005","unstructured":"\u00c5kerstr\u00f6m S, Mousavi-Jazi M, Klingstr\u00f6m J, Leijon M, Lundkvist \u00c5, Mirazimi A (2005) Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 79:1966\u20131969. https:\/\/doi.org\/10.1128\/jvi.79.3.1966-1969.2005","journal-title":"J Virol"},{"key":"1901_CR3","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/jac\/dkv018","volume":"70","author":"MA Al-Bari","year":"2015","unstructured":"Al-Bari MA (2015) Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70:1608\u20131621. https:\/\/doi.org\/10.1093\/jac\/dkv018","journal-title":"J Antimicrob Chemother"},{"key":"1901_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4187\/respcare.05752","volume":"63","author":"F Alessandri","year":"2018","unstructured":"Alessandri F, Pugliese F, Ranieri VM (2018) The role of rescue therapies in the treatment of severe ARDS. Respir Care 63:92\u2013101. https:\/\/doi.org\/10.4187\/respcare.05752","journal-title":"Respir Care"},{"key":"1901_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fmed.2019.00136","volume":"6","author":"F Alhenc-Gelas","year":"2019","unstructured":"Alhenc-Gelas F, Bouby N, Girolami JP (2019) Kallikrein\/K1, kinins, and ACE\/kininase II in homeostasis and in disease insight from human and experimental genetic studies. Ther Implication Front Med 6:136. https:\/\/doi.org\/10.3389\/fmed.2019.00136","journal-title":"Ther Implication Front Med"},{"key":"1901_CR6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/135965350601100803","volume":"11","author":"C Amici","year":"2006","unstructured":"Amici C, di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, Decaro N, Buonavoglia C, Capobianchi MR, Santoro MG (2006) Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther 11:1021\u20131030","journal-title":"Antivir Ther"},{"key":"1901_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/jac\/dkh519","volume":"55","author":"GW Amsden","year":"2005","unstructured":"Amsden GW (2005) Anti-inflammatory effects of macrolides\u2014an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55:10\u201321. https:\/\/doi.org\/10.1093\/jac\/dkh519","journal-title":"J Antimicrob Chemother"},{"key":"1901_CR8","unstructured":"Anakinra: Drug information (2020) uptodate. https:\/\/www.lib.utdo.ir\/contents\/anakinra-drug-information?search=anakinra&source=panel_search_result&selectedTitle=1~101&usage_type=panel&kp_tab=drug_general&display_rank=1#F135491. Accessed May 3 2020"},{"key":"1901_CR9","unstructured":"Baricitinib: Drug information (2020) uptodate.\u00a0https:\/\/www.lib.utdo.ir\/contents\/baricitinib-drug-information?search=baricitinib&source=panel_search_result&selectedTitle=1~19&usage_type=panel&kp_tab=drug_general&display_rank=1#F51514842.\u00a0Accessed 3 May 2020"},{"key":"1901_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00431-016-2694-x","volume":"175","author":"HE Baris","year":"2016","unstructured":"Baris HE et al (2016) The effect of systemic corticosteroids on the innate and adaptive immune system in children with steroid responsive nephrotic syndrome. Eur J Pediatr 175:685\u2013693. https:\/\/doi.org\/10.1007\/s00431-016-2694-x","journal-title":"Eur J Pediatr"},{"key":"1901_CR11","doi-asserted-by":"publisher","first-page":"e13209","DOI":"10.1111\/eci.13209","volume":"50","author":"M Bassetti","year":"2020","unstructured":"Bassetti M, Vena A, Giacobbe DR (2020) The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Investig 50:e13209. https:\/\/doi.org\/10.1111\/eci.13209","journal-title":"Eur J Clin Investig"},{"key":"1901_CR12","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1016\/j.jaci.2008.12.1018","volume":"123","author":"A Beigelman","year":"2009","unstructured":"Beigelman A, Mikols CL, Gunsten S, Cannon CL, Walter MJ (2009) Azithromycin attenuated airway inflammation in a non-infectious mouse model of allergic asthma. J Allergy Clin Immunol 123:S263. https:\/\/doi.org\/10.1016\/j.jaci.2008.12.1018","journal-title":"J Allergy Clin Immunol"},{"key":"1901_CR13","unstructured":"Beware of Fraudulent Coronavirus Tests, Vaccines and Treatments (2020) U.S. Food and Drug Administration https:\/\/www.fda.gov\/consumers\/consumer-updates\/beware-fraudulent-coronavirus-tests-vaccines-and-treatments. Accessed March 24 2020"},{"key":"1901_CR14","doi-asserted-by":"publisher","unstructured":"Bian H et al (2020) Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv 2020.2003.2021.20040691. https:\/\/doi.org\/10.1101\/2020.03.21.20040691","DOI":"10.1101\/2020.03.21.20040691"},{"key":"1901_CR15","unstructured":"Bortezomib: Drug information (2020) uptodate. https:\/\/www.lib.utdo.ir\/contents\/bortezomib-drug-information?search=bortezomib&source=panel_search_result&selectedTitle=1~121&usage_type=panel&kp_tab=drug_general&display_rank=1#F142110. Accessed May 3 2020"},{"key":"1901_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1124\/jpet.110.171876","volume":"335","author":"KJ Broadley","year":"2010","unstructured":"Broadley KJ, Blair AE, Kidd EJ, Bugert JJ, Ford WR (2010) Bradykinin-induced lung inflammation and bronchoconstriction: role in parainfluenze-3 virus-induced inflammation and airway hyperreactivity. J Pharmacol Exp Ther 335:681\u2013692. https:\/\/doi.org\/10.1124\/jpet.110.171876","journal-title":"J Pharmacol Exp Ther"},{"key":"1901_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.010","volume":"114","author":"J Cao","year":"2015","unstructured":"Cao J, Forrest JC, Zhang X (2015) A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs. Antivir Res 114:1\u201310. https:\/\/doi.org\/10.1016\/j.antiviral.2014.11.010","journal-title":"Antivir Res"},{"key":"1901_CR18","doi-asserted-by":"publisher","unstructured":"Cao B et al (2020a) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2001282","DOI":"10.1056\/NEJMoa2001282"},{"key":"1901_CR19","doi-asserted-by":"publisher","unstructured":"Cao W et al (2020b) High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus disease 2019. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofaa102","DOI":"10.1093\/ofid\/ofaa102"},{"key":"1901_CR20","unstructured":"Carfilzomib: Drug information (2020) uptodate. https:\/\/www.lib.utdo.ir\/contents\/carfilzomib-drug-information?search=Carfilzomib&source=panel_search_result&selectedTitle=1~28&usage_type=panel&kp_tab=drug_general&display_rank=1#F49210440. Accessed May 3 2020"},{"key":"1901_CR21","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","volume":"212","author":"JF Chan","year":"2015","unstructured":"Chan JF et al (2015) Treatment with lopinavir\/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:1904\u20131913. https:\/\/doi.org\/10.1093\/infdis\/jiv392","journal-title":"J Infect Dis"},{"key":"1901_CR22","doi-asserted-by":"crossref","unstructured":"Chang RS, W. (2020) Repositioning chloroquine as ideal antiviral prophylactic against COVID-19 - time is now. Preprints doi:10.20944\/preprints202003.0279.v1","DOI":"10.20944\/preprints202003.0279.v1"},{"key":"1901_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1086\/425357","volume":"39","author":"L Chen","year":"2004","unstructured":"Chen L et al (2004) Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis 39:1531\u20131535. https:\/\/doi.org\/10.1086\/425357","journal-title":"Clin Infect Dis"},{"key":"1901_CR24","doi-asserted-by":"publisher","unstructured":"Chen L, Xiong J, Bao L, Shi Y (2020) Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(20)30141-9","DOI":"10.1016\/S1473-3099(20)30141-9"},{"key":"1901_CR25","unstructured":"Chloroquine: Drug information (2020) uptodate. https:\/\/www.lib.utdo.ir\/contents\/chloroquine-drug-information?search=chloroquin&source=panel_search_result&selectedTitle=1~123&usage_type=panel&kp_tab=drug_general&display_rank=1#F54258283. Accessed May 2 2020"},{"key":"1901_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"CM Chu","year":"2004","unstructured":"Chu CM et al (2004) Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252\u2013256. https:\/\/doi.org\/10.1136\/thorax.2003.012658","journal-title":"Thorax"},{"key":"1901_CR27","doi-asserted-by":"publisher","unstructured":"Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents:105932. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105932","DOI":"10.1016\/j.ijantimicag.2020.105932"},{"key":"1901_CR28","unstructured":"Coronavirus Disease 2019 (COVID-19) (2020) https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-issues\/coronavirus-disease-2019-covid-19#mcms. Accessed March 25 2020"},{"key":"1901_CR29","unstructured":"Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention (2020) uptodate. https:\/\/www.uptodate.com\/contents\/coronavirus-disease-2019-covid-19#H1354847215. Accessed Mar 23, 2020."},{"key":"1901_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335:2\u201313. https:\/\/doi.org\/10.1016\/j.mce.2010.04.005","journal-title":"Mol Cell Endocrinol"},{"key":"1901_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1189\/jlb.3RU1116-477R","volume":"101","author":"FU Dawar","year":"2017","unstructured":"Dawar FU, Wu J, Zhao L, Khattak MNK, Mei J, Lin L (2017a) Updates in understanding the role of cyclophilin A in leukocyte chemotaxis. J Leukoc Biol 101:823\u2013826. https:\/\/doi.org\/10.1189\/jlb.3RU1116-477R","journal-title":"J Leukoc Biol"},{"key":"1901_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1189\/jlb.3RU0317-090RR","volume":"102","author":"FU Dawar","year":"2017","unstructured":"Dawar FU, Xiong Y, Khattak MNK, Li J, Lin L, Mei J (2017b) Potential role of cyclophilin A in regulating cytokine secretion. J Leukoc Biol 102:989\u2013992. https:\/\/doi.org\/10.1189\/jlb.3RU0317-090RR","journal-title":"J Leukoc Biol"},{"key":"1901_CR33","doi-asserted-by":"publisher","first-page":"m1086","DOI":"10.1136\/bmj.m1086","volume":"368","author":"M Day","year":"2020","unstructured":"Day M (2020) Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ (Clin Res Ed) 368:m1086. https:\/\/doi.org\/10.1136\/bmj.m1086","journal-title":"BMJ (Clin Res Ed)"},{"key":"1901_CR34","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/asia.201900841","volume":"14","author":"E De Clercq","year":"2019","unstructured":"De Clercq E (2019) New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem Asian J 14:3962\u20133968. https:\/\/doi.org\/10.1002\/asia.201900841","journal-title":"Chem Asian J"},{"key":"1901_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMe1917490","volume":"382","author":"VK Derebail","year":"2020","unstructured":"Derebail VK, Falk RJ (2020) ANCA-associated vasculitis \u2014 refining therapy with plasma exchange and glucocorticoids. N Engl J Med 382:671\u2013673. https:\/\/doi.org\/10.1056\/NEJMe1917490","journal-title":"N Engl J Med"},{"key":"1901_CR36","doi-asserted-by":"publisher","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","volume":"248","author":"AA Elfiky","year":"2020","unstructured":"Elfiky AA (2020) Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 248:117477. https:\/\/doi.org\/10.1016\/j.lfs.2020.117477","journal-title":"Life Sci"},{"key":"1901_CR37","unstructured":"Ershad M, Vearrier D (2019) Ibuprofen Toxicity. StatPearls Publishing LLC.,"},{"key":"1901_CR38","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/s2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21. https:\/\/doi.org\/10.1016\/s2213-2600(20)30116-8","journal-title":"Lancet Respir Med"},{"key":"1901_CR39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1172\/jci107544","volume":"53","author":"AS Fauci","year":"1974","unstructured":"Fauci AS, Dale DC (1974) The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 53:240\u2013246. https:\/\/doi.org\/10.1172\/jci107544","journal-title":"J Clin Invest"},{"key":"1901_CR40","unstructured":"Flowchart diagnosis and treatment of COVID 19 disease at outpatient and inpatient levels (2020) Islamic Republic of Iran Ministry of Health and Medical Education. http:\/\/medcare.behdasht.gov.ir\/uploads\/%D9%86%D8%B3%D8%AE%D9%87_%D8%B4%D8%B4%D9%85_%D9%81%D9%84%D9%88%DA%86%D8%A7%D8%B1%D8%AA.pdf. Accessed April 29 2020"},{"key":"1901_CR41","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nm0796-814","volume":"2","author":"AJ Fox","year":"1996","unstructured":"Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ (1996) Bradykinin\u2013evoked sensitization of airway sensory nerves: A mechanism for ACE\u2013inhibitor cough. Nat Med 2:814\u2013817. https:\/\/doi.org\/10.1038\/nm0796-814","journal-title":"Nat Med"},{"key":"1901_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad B Phys Biol Sci 93:449\u2013463. https:\/\/doi.org\/10.2183\/pjab.93.027","journal-title":"Proc Jpn Acad B Phys Biol Sci"},{"key":"1901_CR43","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:72\u201373. https:\/\/doi.org\/10.5582\/bst.2020.01047","journal-title":"Biosci Trends"},{"key":"1901_CR44","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1038\/s41467-019-13659-4","volume":"10","author":"NC Gassen","year":"2019","unstructured":"Gassen NC et al (2019) SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nat Commun 10:5770. https:\/\/doi.org\/10.1038\/s41467-019-13659-4","journal-title":"Nat Commun"},{"key":"1901_CR45","doi-asserted-by":"publisher","unstructured":"Gautret P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"1901_CR46","doi-asserted-by":"publisher","unstructured":"Ge Y et al (2020) A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. bioRxiv:2020.2003.2011.986836. https:\/\/doi.org\/10.1101\/2020.03.11.986836","DOI":"10.1101\/2020.03.11.986836"},{"key":"1901_CR47","doi-asserted-by":"publisher","unstructured":"Gritti G et al (2020) Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv:2020.2004.2001.20048561. https:\/\/doi.org\/10.1101\/2020.04.01.20048561","DOI":"10.1101\/2020.04.01.20048561"},{"key":"1901_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","volume":"7","author":"Y-R Guo","year":"2020","unstructured":"Guo Y-R et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak \u2013 an update on the status. Mil Med Res 7:11. https:\/\/doi.org\/10.1186\/s40779-020-00240-0","journal-title":"Mil Med Res"},{"key":"1901_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/2049936113501816","volume":"1","author":"JC Hancox","year":"2013","unstructured":"Hancox JC, Hasnain M, Vieweg WVR, Crouse ELB, Baranchuk A (2013) Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports. Ther Adv Infect Dis 1:155\u2013165. https:\/\/doi.org\/10.1177\/2049936113501816","journal-title":"Ther Adv Infect Dis"},{"key":"1901_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1099\/vir.0.061911-0","volume":"95","author":"BJ Hart","year":"2014","unstructured":"Hart BJ et al (2014) Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 95:571\u2013577. https:\/\/doi.org\/10.1099\/vir.0.061911-0","journal-title":"J Gen Virol"},{"key":"1901_CR51","doi-asserted-by":"publisher","unstructured":"He F, Deng Y, Li W (2020) Coronavirus Disease 2019 (COVID-19): What we know? J Med Virol. https:\/\/doi.org\/10.1002\/jmv.25766","DOI":"10.1002\/jmv.25766"},{"key":"1901_CR52","first-page":"1173","volume":"8","author":"JC Ho","year":"2004","unstructured":"Ho JC et al (2004) Pentaglobin in steroid-resistant severe acute respiratory syndrome. Int J Tuberc Lung Dis 8:1173\u20131179","journal-title":"Int J Tuberc Lung Dis"},{"key":"1901_CR53","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue ML et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929\u2013936. https:\/\/doi.org\/10.1056\/NEJMoa2001191","journal-title":"N Engl J Med"},{"key":"1901_CR54","doi-asserted-by":"publisher","unstructured":"Huang Q, Herrmann A (2020) Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV). bioRxiv:2020.2002.2001.930537. https:\/\/doi.org\/10.1101\/2020.02.01.930537","DOI":"10.1101\/2020.02.01.930537"},{"key":"1901_CR55","doi-asserted-by":"publisher","first-page":"e01152","DOI":"10.1128\/aac.01152-17","volume":"61","author":"M Iannetta","year":"2017","unstructured":"Iannetta M, Ippolito G, Nicastri E (2017) Azithromycin shows anti-zika virus activity in human glial cells. Antimicrob Agents Chemother 61:e01152\u2013e01117. https:\/\/doi.org\/10.1128\/aac.01152-17","journal-title":"Antimicrob Agents Chemother"},{"key":"1901_CR56","unstructured":"Imatinib: Drug information (2020) uptodate. https:\/\/www.lib.utdo.ir\/contents\/imatinib-drug-information?search=imatinib&source=panel_search_result&selectedTitle=1~142&usage_type=panel&kp_tab=drug_general&display_rank=1. Accessed May 3 2020"},{"key":"1901_CR57","unstructured":"Immune globulin (Intravenous, subcutaneous, and intramuscular): Drug information (2020) uptodate. www.lib.utdo.ir\/contents\/immune-globulin-intravenous-subcutaneous-and-intramuscular-drug-information?search=immunoglobulin&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1#F11513246. Accessed May 3 2020"},{"key":"1901_CR58","unstructured":"Information for clinicians on therapeutic options for COVID-19 patients (2020) Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/therapeutic-options.html. Accessed March 21 2020"},{"key":"1901_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejphar.2006.03.074","volume":"539","author":"V Iveti\u0107 Tkal\u010devi\u0107","year":"2006","unstructured":"Iveti\u0107 Tkal\u010devi\u0107 V et al (2006) Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 539:131\u2013138. https:\/\/doi.org\/10.1016\/j.ejphar.2006.03.074","journal-title":"Eur J Pharmacol"},{"key":"1901_CR60","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrd1718","volume":"4","author":"P Jagtap","year":"2005","unstructured":"Jagtap P, Szabo C (2005) Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421\u2013440. https:\/\/doi.org\/10.1038\/nrd1718","journal-title":"Nat Rev Drug Discov"},{"key":"1901_CR61","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.isci.2019.07.003","volume":"19","author":"LD Jasenosky","year":"2019","unstructured":"Jasenosky LD et al (2019) The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits ebola virus. iScience 19:1279\u20131290. https:\/\/doi.org\/10.1016\/j.isci.2019.07.003","journal-title":"iScience"},{"key":"1901_CR62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40779-020-0233-6","volume":"7","author":"Y-H Jin","year":"2020","unstructured":"Jin Y-H et al (2020) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 7:4. https:\/\/doi.org\/10.1186\/s40779-020-0233-6","journal-title":"Mil Med Res"},{"key":"1901_CR63","doi-asserted-by":"publisher","unstructured":"Joseph K, Kaplan AP (2005) Formation of bradykinin: a major contributor to the innate inflammatory response. In: Alt FW (ed) Adv Immunol, vol 86. Academic Press, pp 159\u2013208. https:\/\/doi.org\/10.1016\/S0065-2776(04)86005-X","DOI":"10.1016\/S0065-2776(04)86005-X"},{"key":"1901_CR64","unstructured":"Landscape analysis of therapeutics (2020) World Health Organization. https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Table_of_therapeutics_Appendix_17022020.pdf?ua = 1. Accessed 23 March 2020"},{"key":"1901_CR65","doi-asserted-by":"publisher","unstructured":"Larmonier CB, Shehab KW, Laubitz D, Jamwal DR, Ghishan FK, Kiela PR (2016) Transcriptional reprogramming and resistance to colonic mucosal injury in poly (ADP-ribose) polymerase 1 (PARP1)-deficient mice. J Biol Chem 291:8918\u20138930. https:\/\/doi.org\/10.1074\/jbc.M116.714386","DOI":"10.1074\/jbc.M116.714386"},{"key":"1901_CR66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19:149\u2013150. https:\/\/doi.org\/10.1038\/d41573-020-00016-0","journal-title":"Nat Rev Drug Discov"},{"key":"1901_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","volume":"25","author":"FC Lin","year":"2014","unstructured":"Lin FC, Young HA (2014) Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev 25:369\u2013376. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.015","journal-title":"Cytokine Growth Factor Rev"},{"key":"1901_CR68","doi-asserted-by":"publisher","unstructured":"Lin L, Lu L, Cao W, Li T (2020) Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia. Emerging microbes & infections:1-14. https:\/\/doi.org\/10.1080\/22221751.2020.1746199","DOI":"10.1080\/22221751.2020.1746199"},{"key":"1901_CR69","doi-asserted-by":"publisher","first-page":"15199","DOI":"10.1128\/jvi.79.24.15199-15208.2005","volume":"79","author":"HA Lindner","year":"2005","unstructured":"Lindner HA, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T, M\u00e9nard R (2005) The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 79:15199\u201315208. https:\/\/doi.org\/10.1128\/jvi.79.24.15199-15208.2005","journal-title":"J Virol"},{"key":"1901_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.vetmic.2014.11.023","volume":"176","author":"L Liu","year":"2015","unstructured":"Liu L et al (2015) Resolution of the cellular proteome of the nucleocapsid protein from a highly pathogenic isolate of porcine reproductive and respiratory syndrome virus identifies PARP-1 as a cellular target whose interaction is critical for virus biology. Vet Microbiol 176:109\u2013119. https:\/\/doi.org\/10.1016\/j.vetmic.2014.11.023","journal-title":"Vet Microbiol"},{"key":"1901_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/cmi.2015.74","volume":"13","author":"Q Liu","year":"2016","unstructured":"Liu Q, Zhou YH, Yang ZQ (2016) The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 13:3\u201310. https:\/\/doi.org\/10.1038\/cmi.2015.74","journal-title":"Cell Mol Immunol"},{"key":"1901_CR72","unstructured":"Lopinavir and ritonavir: Drug information (2020) uptodate. www.lib.utdo.ir\/contents\/lopinavir-and-ritonavir-drug-information?search=lopinavir%2Fritonavir&source=panel_search_result&selectedTitle=1~57&usage_type=panel&kp_tab=drug_general&display_rank=1#F189746. Accessed May 2 2020"},{"key":"1901_CR73","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 395:1033\u20131034. https:\/\/doi.org\/10.1016\/s0140-6736(20)30628-0","journal-title":"Lancet (London, England)"},{"key":"1901_CR74","first-page":"233","volume":"37","author":"QH Meng","year":"2003","unstructured":"Meng QH, Dong PL, Guo YB, Zhang K, Liang LC, Hou W, Dong JL (2003) Use of glucocorticoid in treatment of severe acute respiratory syndrome cases. Zhonghua yu fang yi xue za zhi [Chin J Prev Med] 37:233\u2013235","journal-title":"Zhonghua yu fang yi xue za zhi [Chin J Prev Med]"},{"key":"1901_CR75","doi-asserted-by":"publisher","first-page":"28698","DOI":"10.1038\/srep28698","volume":"6","author":"M Menzel","year":"2016","unstructured":"Menzel M, Akbarshahi H, Bjermer L, Uller L (2016) Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep 6:28698\u201328698. https:\/\/doi.org\/10.1038\/srep28698","journal-title":"Sci Rep"},{"key":"1901_CR76","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1021\/ci1004916","volume":"51","author":"P Mukherjee","year":"2011","unstructured":"Mukherjee P, Shah F, Desai P, Avery M (2011) Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies. J Chem Inf Model 51:1376\u20131392. https:\/\/doi.org\/10.1021\/ci1004916","journal-title":"J Chem Inf Model"},{"key":"1901_CR77","doi-asserted-by":"publisher","first-page":"e1007296","DOI":"10.1371\/journal.ppat.1007296","volume":"14","author":"D Niemeyer","year":"2018","unstructured":"Niemeyer D, M\u00f6sbauer K, Klein EM, Sieberg A, Mettelman RC, Mielech AM, Dijkman R, Baker SC, Drosten C, M\u00fcller MA (2018) The papain-like protease determines a virulence trait that varies among members of the SARS-coronavirus species. PLoS Pathog 14:e1007296. https:\/\/doi.org\/10.1371\/journal.ppat.1007296","journal-title":"PLoS Pathog"},{"key":"1901_CR78","unstructured":"Nitazoxanide: Drug information (2020) uptodate. www.lib.utdo.ir\/contents\/nitazoxanide-drug-information?search=nitazoxanide&source=panel_search_result&selectedTitle=1~28&usage_type=panel&kp_tab=drug_general&display_rank=1#F201730. Accessed May 2 2020"},{"key":"1901_CR79","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s1473-3099(14)70920-x","volume":"14","author":"AS Omrani","year":"2014","unstructured":"Omrani AS et al (2014) Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14:1090\u20131095. https:\/\/doi.org\/10.1016\/s1473-3099(14)70920-x","journal-title":"Lancet Infect Dis"},{"key":"1901_CR80","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrmicro2147","volume":"7","author":"S Perlman","year":"2009","unstructured":"Perlman S, Netland J (2009) Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7:439\u2013450. https:\/\/doi.org\/10.1038\/nrmicro2147","journal-title":"Nat Rev Microbiol"},{"key":"1901_CR81","unstructured":"Physicians work out treatment guidelines for coronavirus (2020) Korea Biomedical Review.http:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=7428. Accessed 13 Feb 2020"},{"key":"1901_CR82","unstructured":"Remdesivir (United States: Investigational agent; refer to Prescribing and Access Restrictions): Drug information (2020) uptodate. www.lib.utdo.ir\/contents\/remdesivir-united-states-investigational-agent-refer-to-prescribing-and-access-restrictions-drug-information?search=Remdesivir&source=panel_search_result&selectedTitle=1~12&usage_type=panel&kp_tab=drug_general&display_rank=1#F54342497. Accessed May 2 2020"},{"key":"1901_CR83","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/s0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England) 395:e30\u2013e31. https:\/\/doi.org\/10.1016\/s0140-6736(20)30304-4","journal-title":"Lancet (London, England)"},{"key":"1901_CR84","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"JF Rossignol","year":"2014","unstructured":"Rossignol JF (2014) Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir Res 110:94\u2013103. https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.014","journal-title":"Antivir Res"},{"key":"1901_CR85","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","volume":"9","author":"JF Rossignol","year":"2016","unstructured":"Rossignol JF (2016) Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 9:227\u2013230. https:\/\/doi.org\/10.1016\/j.jiph.2016.04.001","journal-title":"J Infect Public Health"},{"key":"1901_CR86","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nri2802","volume":"10","author":"BT Rouse","year":"2010","unstructured":"Rouse BT, Sehrawat S (2010) Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol 10:514\u2013526. https:\/\/doi.org\/10.1038\/nri2802","journal-title":"Nat Rev Immunol"},{"key":"1901_CR87","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russell","year":"2020","unstructured":"Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395:473\u2013475. https:\/\/doi.org\/10.1016\/S0140-6736(20)30317-2","journal-title":"Lancet"},{"key":"1901_CR88","unstructured":"Sarilumab: Drug information (2020) uptodate. https:\/\/www.lib.utdo.ir\/contents\/sarilumab-drug-information?search=sarilumab&source=panel_search_result&selectedTitle=1~13&usage_type=panel&kp_tab=drug_general&display_rank=1#F50136516. Accessed May 3 2020"},{"key":"1901_CR89","first-page":"3450","volume":"44","author":"A Schoegler","year":"2014","unstructured":"Schoegler A et al (2014) Antiviral activity of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 44:3450","journal-title":"Eur Respir J"},{"key":"1901_CR90","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1183\/09031936.00102014","volume":"45","author":"A Sch\u00f6gler","year":"2014","unstructured":"Sch\u00f6gler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C, Kieninger E, Jung A, Moeller A, Geiser T, Regamey N, Alves MP (2014) Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 45:45\u2013439. https:\/\/doi.org\/10.1183\/09031936.00102014","journal-title":"Eur Respir J"},{"key":"1901_CR91","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1753465815599345","volume":"9","author":"RJ Searcy","year":"2015","unstructured":"Searcy RJ, Morales JR, Ferreira JA, Johnson DW (2015) The role of inhaled prostacyclin in treating acute respiratory distress syndrome. Ther Adv Respir Dis 9:302\u2013312. https:\/\/doi.org\/10.1177\/1753465815599345","journal-title":"Ther Adv Respir Dis"},{"key":"1901_CR92","doi-asserted-by":"publisher","unstructured":"Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W (2020) Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. https:\/\/doi.org\/10.12932\/ap-200220-0773","DOI":"10.12932\/ap-200220-0773"},{"key":"1901_CR93","doi-asserted-by":"publisher","unstructured":"Shen K et al (2020) Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts\u2019 consensus statement. World J Pediatr. https:\/\/doi.org\/10.1007\/s12519-020-00343-7","DOI":"10.1007\/s12519-020-00343-7"},{"key":"1901_CR94","unstructured":"Siltuximab: Drug information (2020) uptodate. https:\/\/www.lib.utdo.ir\/contents\/siltuximab-drug-information?search=Siltuximab&source=panel_search_result&selectedTitle=1~6&usage_type=panel&kp_tab=drug_general&display_rank=1#F24801298. Accessed May 3 2020"},{"key":"1901_CR95","first-page":"795","volume":"25","author":"JA Silva","year":"2007","unstructured":"Silva JA, Silva MB, Skare TL (2007) Chloroquine and QTc interval. Clin Exp Rheumatol 25:795","journal-title":"Clin Exp Rheumatol"},{"key":"1901_CR96","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3310\/hta14460-02","volume":"14","author":"AK Simonds","year":"2010","unstructured":"Simonds AK et al (2010) Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess (Winchester, England) 14:131\u2013172. https:\/\/doi.org\/10.3310\/hta14460-02","journal-title":"Health Technol Assess (Winchester, England)"},{"key":"1901_CR97","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.dsx.2020.03.011","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh A, Shaikh A, Singh R, Misra A (2020) Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 14:241\u2013246. https:\/\/doi.org\/10.1016\/j.dsx.2020.03.011","journal-title":"Diabetes Metab Syndr"},{"key":"1901_CR98","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1099\/jgv.0.001047","volume":"99","author":"JM Sisk","year":"2018","unstructured":"Sisk JM, Frieman MB, Machamer CE (2018) Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol 99:619\u2013630. https:\/\/doi.org\/10.1099\/jgv.0.001047","journal-title":"J Gen Virol"},{"key":"1901_CR99","doi-asserted-by":"publisher","unstructured":"Soraya H (2020) Prophylactic use of chloroquine may impair innate immune system response against SARS-Cov-2. Pharm Sci. https:\/\/doi.org\/10.34172\/PS.2020.29","DOI":"10.34172\/PS.2020.29"},{"key":"1901_CR100","doi-asserted-by":"publisher","unstructured":"Su Z, Wu Y (2020) A multiscale and comparative model for receptor binding of 2019 novel coronavirus and the implication of its life cycle in host cells. bioRxiv 2020.2002.2020.958272. https:\/\/doi.org\/10.1101\/2020.02.20.958272","DOI":"10.1101\/2020.02.20.958272"},{"key":"1901_CR101","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/s1470-2045(17)30607-1","volume":"18","author":"NL Syn","year":"2017","unstructured":"Syn NL, Teng MWL, Mok TSK, Soo RA (2017) De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 18:e731\u2013e741. https:\/\/doi.org\/10.1016\/s1470-2045(17)30607-1","journal-title":"Lancet Oncol"},{"key":"1901_CR102","doi-asserted-by":"publisher","first-page":"m1256","DOI":"10.1136\/bmj.m1256","volume":"368","author":"JH Tanne","year":"2020","unstructured":"Tanne JH (2020) Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ (Clin Res ed) 368:m1256. https:\/\/doi.org\/10.1136\/bmj.m1256","journal-title":"BMJ (Clin Res ed)"},{"key":"1901_CR103","doi-asserted-by":"publisher","unstructured":"Tian X et al (2020) Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. bioRxiv:2020.2001.2028.923011. https:\/\/doi.org\/10.1101\/2020.01.28.923011","DOI":"10.1101\/2020.01.28.923011"},{"key":"1901_CR104","unstructured":"Tocilizumab: Drug information (2020) uptodate. https:\/\/www.lib.utdo.ir\/contents\/tocilizumab-drug-information?search=tocilizumab&source=panel_search_result&selectedTitle=1~111&usage_type=panel&kp_tab=drug_general&display_rank=1#F9773705. Accessed May 3 2020"},{"key":"1901_CR105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https:\/\/doi.org\/10.1186\/1743-422X-2-69","journal-title":"Virol J"},{"key":"1901_CR106","doi-asserted-by":"publisher","unstructured":"Wang K et al (2020a) SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv 2020.2003.2014.988345. https:\/\/doi.org\/10.1101\/2020.03.14.988345","DOI":"10.1101\/2020.03.14.988345"},{"key":"1901_CR107","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M et al (2020b) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"1901_CR108","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren TK et al (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381\u2013385. https:\/\/doi.org\/10.1038\/nature17180","journal-title":"Nature"},{"key":"1901_CR109","first-page":"383","volume":"83","author":"ML Webel","year":"1974","unstructured":"Webel ML, Ritts RE Jr, Taswell HF, Danadio JV Jr, Woods JE (1974) Cellular immunity after intravenous administration of methylprednisolone. J Lab Clin Med 83:383\u2013392","journal-title":"J Lab Clin Med"},{"key":"1901_CR110","unstructured":"WHO launches global megatrial of the four most promising coronavirus treatments (2020) Science. https:\/\/www.sciencemag.org\/news\/2020\/03\/who-launches-global-megatrial-fourmost-promising-coronavirus-treatments. Accessed 22 Mar 2020"},{"key":"1901_CR111","doi-asserted-by":"publisher","unstructured":"Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. Jama. https:\/\/doi.org\/10.1001\/jama.2020.2648","DOI":"10.1001\/jama.2020.2648"},{"key":"1901_CR112","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/aac.48.7.2693-2696.2004","volume":"48","author":"CJ Wu","year":"2004","unstructured":"Wu CJ et al (2004) Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother 48:2693\u20132696. https:\/\/doi.org\/10.1128\/aac.48.7.2693-2696.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"1901_CR113","doi-asserted-by":"publisher","unstructured":"Wu A et al (2020) Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. https:\/\/doi.org\/10.1016\/j.chom.2020.02.001","DOI":"10.1016\/j.chom.2020.02.001"},{"key":"1901_CR114","doi-asserted-by":"publisher","unstructured":"Xu J, Shi PY, Li H, Zhou J (2020) Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00052","DOI":"10.1021\/acsinfecdis.0c00052"},{"key":"1901_CR115","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/ijbs.24612","volume":"14","author":"H Xue","year":"2018","unstructured":"Xue H, Li J, Xie H, Wang Y (2018) Review of drug repositioning approaches and resources. Int J Biol Sci 14:1232\u20131244. https:\/\/doi.org\/10.7150\/ijbs.24612","journal-title":"Int J Biol Sci"},{"key":"1901_CR116","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1128\/jvi.78.11.5642-5650.2004","volume":"78","author":"ZY Yang","year":"2004","unstructured":"Yang ZY et al (2004) pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 78:5642\u20135650. https:\/\/doi.org\/10.1128\/jvi.78.11.5642-5650.2004","journal-title":"J Virol"},{"key":"1901_CR117","doi-asserted-by":"publisher","unstructured":"Yao X et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa237","DOI":"10.1093\/cid\/ciaa237"},{"key":"1901_CR118","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1172\/jci107591","volume":"53","author":"DT Yu","year":"1974","unstructured":"Yu DT, Clements PJ, Paulus HE, Peter JB, Levy J, Barnett EV (1974) Human lymphocyte subpopulations. Effect of corticosteroids. J Clin Invest 53:565\u2013571. https:\/\/doi.org\/10.1172\/jci107591","journal-title":"J Clin Invest"},{"key":"1901_CR119","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.micinf.2020.01.003","volume":"22","author":"F Yu","year":"2020","unstructured":"Yu F, Du L, Ojcius DM, Pan C, Jiang S (2020) Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect 22:74\u201379. https:\/\/doi.org\/10.1016\/j.micinf.2020.01.003","journal-title":"Microbes Infect"},{"key":"1901_CR120","doi-asserted-by":"publisher","unstructured":"Zhang Q, Wang Y, Qi C, Shen L, Li J (2020a) Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.25733","DOI":"10.1002\/jmv.25733"},{"key":"1901_CR121","doi-asserted-by":"publisher","unstructured":"Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T (2020b) Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases. Virol Sin. https:\/\/doi.org\/10.1007\/s12250-020-00203-8","DOI":"10.1007\/s12250-020-00203-8"},{"key":"1901_CR122","doi-asserted-by":"publisher","unstructured":"Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol. https:\/\/doi.org\/10.1038\/s41569-020-0360-5","DOI":"10.1038\/s41569-020-0360-5"},{"key":"1901_CR123","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270\u2013273. https:\/\/doi.org\/10.1038\/s41586-020-2012-7","journal-title":"Nature"},{"key":"1901_CR124","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1365-2567.2004.01991.x","volume":"113","author":"B Zingarelli","year":"2004","unstructured":"Zingarelli B, Hake PW, Burroughs TJ, Piraino G, O'Connor M, Denenberg A (2004) Activator protein-1 signalling pathway and apoptosis are modulated by poly (ADP-ribose) polymerase-1 in experimental colitis. Immunology 113:509\u2013517. https:\/\/doi.org\/10.1111\/j.1365-2567.2004.01991.x","journal-title":"Immunology"},{"key":"1901_CR125","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"A Zumla","year":"2016","unstructured":"Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY (2016) Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 15:327\u2013347. https:\/\/doi.org\/10.1038\/nrd.2015.37","journal-title":"Nat Rev Drug Discov"},{"key":"1901_CR126","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S0140-6736(20)30305-6","volume":"395","author":"A Zumla","year":"2020","unstructured":"Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M (2020) Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 395:e35\u2013e36. https:\/\/doi.org\/10.1016\/S0140-6736(20)30305-6","journal-title":"Lancet"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-020-01901-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-020-01901-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-020-01901-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T05:32:45Z","timestamp":1666589565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-020-01901-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":126,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1901"],"URL":"https:\/\/doi.org\/10.1007\/s00210-020-01901-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}